An Epidemiological, Prospective Cohort Study to Generate Real-world Evidence in Patients with HR*/HER2- Advanced Breast Cancer Treated in the First-line Setting as per Current Standard of Care with an Endocrine-based Palbociclib Combination Therapy

A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications. (PHOEBUS)

A randomized phase II study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor based endocrine therapy as first line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling

Prospektives, akademisches, translationales Forschungs-Netzwerk zur Optimierung der onkologischen Gesundheitsversorgung Qualität in der adjuvanten und der fortgeschrittenen/metastasierten Situation: Gesundheitsforschung, Pharmakogenomik, Biomarker, Gesundheitsökonomie PRAEGNANT Brustkrebs: Fortgeschritten/ Metastasierend

Prospektive Studie zum multiplen Myelom: eine Anwendungsbeurteilung

PRESS -PAR: Early detection and PREvention of Symptomatic postSurgical hypoPARathyroidism after thyroid surgery

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Evaluation der DIGA consilium care bei Patientinnen mit Her 2 positiven Brustkrebs während einer Chemotherapie in Kombination mit einer Her 2 zielgerichteten Antikörper Therapie

Real world experience of patients with metastatic castration resistant prostate Cancer treated with Olaparib+Abiraterone